Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2020 update
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• "Non merci"
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Refer a friend or colleague
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

The covid-19 messenger RNA vaccine from Moderna: as with the tozinameran vaccine (Comirnaty°, Pfizer/BioNTech), limited data and unanswered questions  NEWS UPDATE  As of early January 2021, the covid-19 vaccine mRNA-1273 Sars-CoV-2, from the pharmaceutical company Moderna, is expected to be approved for use in the European Union. In France, this vaccine is to be offered first to elderly residents of nursing homes and similar facilities, and to certain health professionals. What are the main evaluation data obtained with this vaccine in these populations?  06 January 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ The covid-19 messenger RNA vaccine tozinameran (Comirnaty°, from Pfizer and BioNTech) in elderly patients: limited data, many uncertainties  NEWS UPDATE  The vaccination campaign against the covid-19 epidemic is launching in late December 2020. The first populations to whom the French authorities have chosen to offer this covid-19 messenger RNA vaccine (marketed by the pharmaceutical companies Pfizer and BioNTech) are nursing home residents and certain health professionals who work in these facilities. What are the main data from the clinical evaluation of this vaccine in this population? 23 December 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of news updates featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view. 06 January 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ SSRI antidepressants and pregnancy: long-term neuropsychiatric disorders in exposed children? FEATURED REVIEW Data available in 2017 suggested that in utero exposure to SSRI antidepressants increases the risk of autism. Do we have a clearer idea in 2020 of the long-term neuropsychiatric harms to the unborn child posed by the use of SSRI antidepressants during pregnancy? Full review (3 pages) available for download by subscribers. 1 January 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In the January issue of Prescrire International: Dasatinib (Sprycel° and other brands) in children with acute lymphoblastic leukaemia FREE DOWNLOAD Dasatinib has been granted marketing authorisation in the European Union as first-line therapy added to chemotherapy for children with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Full text available for free download. 1 January 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ A two-step approach EDITORIAL In the midst of the covid-19 crisis, Prescrire is fulfilling its mission via a two-step approach. Rapidly sharing key information, distinguishing fact from hypothesis and opinion. Then helping healthcare professionals to make rational choices, based on documented evidence rather than wishful thinking. Taking care not to confuse urgent action with undue haste. 1 January 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Treatment-resistant depression: avoid esketamine (Spravato°) Esketamine nasal spray (Spravato°) has been authorised for use in so-called "treatment-resistant" depression. Its efficacy is uncertain, and its harm-benefit balance is unfavourable due to serious adverse effects including neuropsychiatric and cardiac disorders. 1 January 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Adverse effects of cancer drugs: often downplayed in articles reporting the results of clinical trials The adverse effects that occurred during clinical trials are often omitted in articles, or described using subjective terms. 1 January 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Updated review of "Drugs to avoid, in the name of better patient care" is published by independent French journal Prescrire The independent French medical journal Prescrire has published its annual review of "Drugs to avoid", identifying drugs that are clearly more harmful than beneficial. The full report will be published in English in the February 2020 issue of Prescrire International. 1 December 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON Ebola vaccine rVSV-Zebov during an outbreak of Ebola virus disease • Blinatumomab in acute lymphoblastic leukaemia in remission: not acceptable • Smoking cessation: toxic dose levels of certain drugs • Treatment of deep vein thrombosis and pulmonary embolism • Drugs to avoid in 2021... > Subscribe now 1 January 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Top Texts of 2020", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this brand new sampling of texts from Prescrire International, a wholly independent monthly journal written by and for healthcare professionals. Inside, top articles from our "New Products", "Adverse Effects" and "Reviews" sections, plus our annual update of drugs to avoid. > Click here for your free copy 1 August 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on Facebook and Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on Facebook or > Follow us on Twitter 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International Subscribe now Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page